Introduction: The signal transducer and activator of transcription (STAT1) gain-of-function (GOF) syndrome accounts for most cases of chronic mucocutaneous candidiasis but is characterized by a broader clinical phenotype that may include bacterial, viral, or invasive fungal infections, autoimmunity, autoinflammatory manifestations, vascular complications, or malignancies. The severity of lymphopenia may vary and influence the infectious morbidity. Methods: In our cohort of seven STAT1-GOF patients, we investigated the mechanisms that may determine T lymphopenia, we characterized the interferon gene signature (IGS) and analyzed the effect of ruxolitinib in reverting the immune dysregulation. Results: STAT1-GOF patients exhibited increased T lymphocyte apoptosis that was significantly augmented in both resting conditions and following stimulation with mitogens and IFNα, as evaluated by flow cytometry by Annexin V/ Propidium iodide assay. The JAK inhibitor ruxolitinib significantly reduced the IFNα-induced hyperphosphorylation of STAT1 and reverted the stimulation-induced T-cell apoptosis, in vitro. In two adult STAT1-GOF patients, the JAKinib treatment ameliorated chronic mucocutaneous candidiasis and lymphopenia. Most STAT1-GOF patients, particularly those who had autoimmunity, presented increased IGS that significantly decreased in the two patients during ruxolitinib treatment. Conclusion: In STAT1-GOF patients, T lymphocyte apoptosis is increased, and T lymphopenia may determine higher risk of severe infections. The JAKinib target therapy should be evaluated to treat severe chronic candidiasis and lymphopenia, and to downregulate the IFNs in patients with autoinflammatory or autoimmune manifestations.
Human tonsils from the nasopharyngeal mucosa mount frontline antibody responses, including IgD secretion by IgD+IgM– plasma cells (IgD-PCs). The developmental origins and functional significance of these IgD responses remain poorly understood. Here, we show that most IgD-PCs clonally emerge from a heterogeneous population of IgD class-switched IgD+IgM– memory (IgD-ME) B cells that reside within the epithelial, subepithelial, and interfollicular areas of the nasopharyngeal mucosa and share transcriptional and phenotypic properties with atypical B cells. These IgD-ME B cells arise from a mutation-intensive pathway that involves integrated innate and adaptive signals and engenders reactivities to respiratory commensal bacteria, common environmental antigens, and allergens. Such reactivities weaken in germline IgD revertants. Thus, the secreted IgD response heavily relies on nasopharyngeal mucosal IgD-ME B cells via a germinal center–imprinted mutational program that presumably enhances mucosal homeostasis and environmental tolerance.
Introduction. The signal transducer and activator of transcription (STAT1) gain of function (GOF) syndrome accounts for most cases of chronic mucocutaneous candidiasis but is characterized by a broader clinical phenotype that may include bacterial, viral, or fungal infections, autoimmunity, autoinflammatory manifestations, vascular complications, or malignancies. The spectrum of immunological abnormalities may vary and influence the infectious morbidity. Methods. We investigated the mechanisms that may determine T lymphopenia in STAT1-GOF patients and evaluate the interferon signature in patients exhibiting autoimmunity. Results. STAT1-GOF patients may manifest T lymphopenia particularly by adult age. We observed how the hyperactivation of STAT1 associated with a disrupted pattern of apoptosis as the stimulation with IFNα increased the expression of markers of apoptosis via caspase activation and significantly increased the apoptosis of T cells in STAT1-GOF patients. The use of a JAK inhibitor, ruxolitinib, was effective in controlling the hyperphosphorylation of STAT1 and reducing T cells apoptosis. This effect was translated in vivo to the increase of lymphocyte count in two treated adult patients. Similarly, ruxolitinib modulated the activation of interferon signature following IFNα stimulation, that may correlate with autoimmune complications. Conclusion. In STAT1-GOF patients, the hyperactivation of IFNα-mediated response may contribute to T lymphopenia throughout increased cellular apoptosis and determine immunedysregulation manifestations. Our results support the use of JAK inhibitor to revert the pathogenesis of T lymphopenia thus reducing the risk of life-threatening infections and suggest the evaluation of interferon score in STAT1-GOF patients as a marker to monitor the risk of autoimmune manifestations.
Background: Multisystem Inflammatory Syndrome in Children (MIS-C) is a severe complication of SARS-CoV-2 infection caused by hyperactivation of the immune system. Methods: this is a retrospective analysis of clinical data, biochemical parameters, and immune cell subsets in 40 MIS-C patients from hospital admission to outpatient long-term follow-up. Results: MIS-C patients had elevated inflammatory markers, associated with T- and NK-cell lymphopenia, a profound depletion of dendritic cells, and altered monocyte phenotype at disease onset, while the subacute phase of the disease was characterized by a significant increase in T- and B-cell counts and a rapid decline in activated T cells and terminally differentiated B cells. Most of the immunological parameters returned to values close to the normal range during the remission phase (20–60 days after hospital admission). Nevertheless, we observed a significantly reduced ratio between recently generated and more differentiated CD8+ T- and B-cell subsets, which partially settled at longer-term follow-up determinations. Conclusions: The characterization of lymphocyte distribution in different phases of MIS-C may help to understand the course of diseases that are associated with dysregulated immune responses and to calibrate prompt and targeted treatments.
18 March 2026 in The Pediatric Infectious Disease Journal
Background: Human noroviruses are a leading cause of acute gastroenteritis worldwide, with GII.4 Sydney 2012 [P16], being the predominant circulating genotype in Italy in recent years. Outbreaks in pediatric hospital wards represent a major public health concern. Methods: Eight stool samples collected between November 2023 and February 2024 at Brescia Civic Hospital were analyzed by real-time polymerase chain reaction, sequence-independent single-primer amplification and next-generation sequencing. Results: All isolates belonged to GII.4 Sydney 2012 [P16] genotype. Five isolates from December 2023 clustered tightly together, confirming a nosocomial outbreak with near-complete sequence identity. Isolates from November 2023, January 2024 and February 2024 were phylogenetically distinct, with 1 isolate (January 2024) clustering in a completely separated tree portion, carrying 30 amino acid substitutions and 237 synonymous mutations. Conclusions: Our analysis confirmed a nosocomial outbreak and underscored the substantial intra-genotypic diversity of GII.4 Sydney 2012 [P16] genotype. These findings highlight the importance of rapid diagnosis, infection control measures and continuous genomic surveillance to track the evolution and global circulation of epidemic noroviruses.
About Me
Laura Dotta, MD, Pediatrician, Researcher in the Department of Clinical and Experimental Sciences: inborn errors of immunity.
Laura Dotta, MD, Pediatrician, Researcher in the Department of Clinical and Experimental Sciences: inborn errors of immunity.